Advertisement

Rodent Models of Oxygen-Induced Retinopathy

  • Susan E. Yanni
  • Gary W. McCollum
  • John S. Penn

Abstract

Retinopathy of prematurity (ROP), a condition affecting premature infants, is characterized by pathological ocular angiogenesis, or retinal neovasculariztion (NV). Much of what is known about the development of the retinal vasculature and the progression of ROP has been acquired through the use of animal models of oxygen-induced retinopathy (OIR), which approximate ROP. Animal models of OIR have provided a wealth of information regarding the cellular and molecular pathogenesis of ROP. This information has contributed to a better understanding of other, non-ocular, neovascular conditions. The aim of this chapter is to explore the significance of the two most prevalent animal models of OIR, the mouse and the rat.

Keywords

Vascular Endothelial Cell Growth Factor Vascular Endothelial Cell Growth Factor mRNA Vascular Endothelial Cell Growth Factor Retinal Vasculature Retinal Neovascularization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    T. L. Terry, Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: I, preliminary report, Am. J. Ophthalmol. 25, 203-204 (1942).Google Scholar
  2. 2.
    K. Campbell, Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach, Med. J. Austral. 2(2), 48-50 (1951).PubMedGoogle Scholar
  3. 3.
    A. Patz, L. E. Hoeck, and E. De La Cruz, Studies on the effect of high oxygen administration in retrolental fibroplasia: I, nursery observations, Am. J. Ophthalmol. 35 (9), 1248-1253 (1952).PubMedGoogle Scholar
  4. 4.
    L. J. Gyllensten and B. E. Hellstrom, Retrolental fibroplasias: animal experiments, Acta. Paediatr. 41 (6), 577-582 (1952).PubMedGoogle Scholar
  5. 5.
    A. Patz, A. Eastham, D. Higginbotham, and T. Kleh, Oxygen studies in retrolental fibroplasia: II, the production of the microscopic changes of retrolental fibroplasia in experimental animals, Am. J. Ophthalmol. 36 (11), 1511-1522 (1953).PubMedGoogle Scholar
  6. 6.
    N. Ashton, B. Ward, and G. Serpell, Role of oxygen in the genesis of retrolental fibroplasia: a preliminary report, Br. J. Ophthalmol. 37 (9), 513-520 (1953).PubMedCrossRefGoogle Scholar
  7. 7.
    N. Ashton, B. Ward, and G. Serpell, Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasias, Br. J. Ophthalmol. 38 (7), 397-432 (1954).PubMedCrossRefGoogle Scholar
  8. 8.
    E. M. Hatfield, Blindness in infants and young children, Sight Sav. Rev. 42 (2), 69-89 (1972).Google Scholar
  9. 9.
    D. L. Gibson, S. B. Sheps, M. T. Schechter, S. Wiggins, and A. Q. McCormick, Retinopathy of prematurity: a new epidemic, Pediatrics 83 (4), 486-492 (1989).PubMedGoogle Scholar
  10. 10.
    W. A. Silverman, Retrolental fibroplasia: a modern parable. New York: Grune and Stratton,Google Scholar
  11. 11.
    A. Madan, Angiogenesis and antiangiogenesis in the neonate: relevance to retinopathy, Neo. Reviews 4, 356-363 (2003).Google Scholar
  12. 12.
    A. Madan and J. S. Penn, Animal models of oxygen-induced retinopathy, Frontiers in Biosciences 8, 1030-1043 (2003).CrossRefGoogle Scholar
  13. 13.
    A. M. Roth, Retinal vascular development in premature infants, Am. J. Ophthalmol. 84 (5), 636-640 (1977).PubMedGoogle Scholar
  14. 14.
    R. Foos and S. Kopelow, Development of retinal vasculature in paranatal infants, Surv. Ophthalmol. 18, 117-127 (1973).Google Scholar
  15. 15.
    I. Michaelson, The mode of development of the vascular system of the retina, with some observations in its significance for certain retinal diseases, Trans. Ophthalmol. Soc. U.K. 68, 137-180 (1948).Google Scholar
  16. 16.
    D. K. Coats, E. A. Paysse, and P. G. Steinkuller, Threshold retinopathy of prematurity in neonates less than 25 weeks’ estimated gestational age, J. AAPOS. 4 (3), 183-185 (2000).PubMedCrossRefGoogle Scholar
  17. 17.
    M. Fruttiger, Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis, Invest. Ophthalmol. Vis. Sci. 43 (2), 522-527 (2002).PubMedGoogle Scholar
  18. 18.
    T. Chan-Ling, D. S. McLeod, S. Hughes, L. Baxter, Y. Chu, T Hasegawa, and G. A. Lutty, Astrocyte-endothelial cell relationships during human retinal vascular development, Invest. Ophthalmol. Vis. Sci. 45 (6), 2020-2032 (2004).PubMedCrossRefGoogle Scholar
  19. 19.
    L. Gyllensten and B. Hellstrom, Experimental approach to the pathogenesis of retrolental fibroplasias: I. Changes of the eyes induced by exposure of newborn mice to concentrated oxygen, Acta. Pediat. 43 (100), 131-148 (1954).Google Scholar
  20. 20.
    L. Gyllensten and B. Hellstrom, Experimental approach to the pathogenesis of retrolental fibroplasia II. The influence of the developmental maturity in oxygen-induced changes in the mouse eye, Am. J. Ophthalmol. 39 (4, Part 1), 475-488 (1955).PubMedGoogle Scholar
  21. 21.
    A. Patz, A. Eastham, D. H. Higgenbotham, and T. Kleh, Oxygen studies in retrolental fibroplasia II. The production of the microscopic changes of retrolental fibroplasia in experimental animals, Am. J. Ophthalmol. 36 (11), 1511-1522 (1953).PubMedGoogle Scholar
  22. 22.
    P. M. Bischoff, S. D. Wajer, and R. W. Flower, Scanning electron microscopic studies of the hyaloid vascular system in newborn mice exposed to O2 and CO2, Graefes Arch. Clin. Exp. Ophthalmol. 220 (6), 257-263 (1983).PubMedCrossRefGoogle Scholar
  23. 23.
    L. E. Smith, E. Wesolowski, A. McLellan, S. K. Kostyk, R. D’Amato, R. Sullivan, and P. A. D’Amore, Oxygen-induced retinopathy in the mouse, Invest. Ophthalmol. Vis. Sci. 35 (1), 101-111 (1994).PubMedGoogle Scholar
  24. 24.
    R. M. Rohan, A. Fernandez, T. Udagawa, J. Yuan, and R. J. D’Amato, Genetic heterogeneity of angiogenesis in mice, FASEB J. 14 (7), 871-876 (2000).PubMedGoogle Scholar
  25. 25.
    M. S. Rogers, R. M. Rohan, A. E. Birsner, and R. J. D’Amato, Genetic loci that control vascular endothelial growth factor-induced angiogenesis, FASEB J. 17 (4), 2112-2114 (2003).PubMedGoogle Scholar
  26. 26.
    C. K. Chan, L. N. Pham, J. Zhou, C. Spee, S. J. Ryan, and D. R. Hinton, Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization, Lab. Invest. 85 (6), 721-733 (2005).PubMedCrossRefGoogle Scholar
  27. 27.
    S. Claxton and M. Fruttiger, Role of arteries in oxygen induced vaso-obliteration, Exp. Eye Res 77 (3), 305-311 (2003).PubMedCrossRefGoogle Scholar
  28. 28.
    G. A. Gole, Animal models of retinopathy of prematurity. In: Silverman WA, Flynn JT, eds. Contemporary Issues in Fetal and Neonatal Medicine 2: Retinopathy of Prematurity. Boston: Blackwell Scientific Publishers; 1985: 53-95.Google Scholar
  29. 29.
    A. Patz, Oxygen studies in retrolental fibroplasia IV: clinical and experimental observations, Am. J. Ophthalmol. 38 (3), 291-308 (1954).PubMedGoogle Scholar
  30. 30.
    N. Ashton and R. Blach, Studies in developing retinal vessels VIII: effect of oxygen on the vessels of the ratling, Br. J. Ophthalmol. 45, 321-340 (1961).PubMedCrossRefGoogle Scholar
  31. 31.
    J. S. Penn, B. L. Tolman, and L. A. Lowery, Variable oxygen exposure causes preretinal neovascularization in the newborn rat, Invest. Ophthalmol. Vis. Sci. 34 (3), 576-585 (1993).PubMedGoogle Scholar
  32. 32.
    J. S. Penn, M. M. Henry, and B. L. Tolman, Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat, Pediatr. Res. 36 (6), 724-731 (1994).PubMedCrossRefGoogle Scholar
  33. 33.
    G. Gao, Y. Li, J. Fant, C. E. Crosson, S. P. Becerra, and J. X. Ma, Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization, Diabetes 51 (4), 1218-1225 (2002).PubMedCrossRefGoogle Scholar
  34. 34.
    S. X. Zhang, J. X. Ma, J. Sima, Y. Chen, M. S. Hu, A. Ottlecz, and G. N. Lambrou, Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy, Am. J. Pathol. 166 (1), 313-321 (2005).PubMedGoogle Scholar
  35. 35.
    B. N. Floyd, D. A. Leske, S. M. Wren, M. Mookadam, M. P. Fautsch, and J. M. Holmes, Differences between rat strains in models of retinopathy of prematurity, Mol. Vis. 11, 524-530 (2005).PubMedGoogle Scholar
  36. 36.
    A. Kitzmann, D. A. Leske, Y. Chen, A. Kendall, W. Lanier, and J. Holmes, Incidence and severity of neovascularization in oxygen-and metabolic acidosis-induced retinopathy depend on rat source, Curr. Eye Res. 25, 215-220 (2002).PubMedCrossRefGoogle Scholar
  37. 37.
    L. I. Larrazabal, and J. S. Penn, Study of ocular vasculature in the newborn rat by fluorescein angiography, J. Ophthal. Phot. 11, 49-52 (1989).Google Scholar
  38. 38.
    L. I. Larrazabal and J. S. Penn, Fluorescein angiography in the newborn rat: Implications in oxygen-induced retinopathy, Invest. Ophthalmol. Vis. Sci. 31 (5), 810-818 (1990).PubMedGoogle Scholar
  39. 39.
    J. S. Penn and B. D. Johnson, Fluorescein angiography as a means of assessing retinal vascular pathology in oxygen-exposed newborn rats, Curr. Eye. Res. 12 (6), 561-570 (1993).PubMedCrossRefGoogle Scholar
  40. 40.
    J. S. Penn, B. L. Tolman, L. A. Lowery, and C. A. Koutz, Oxygen-induced retinopathy in the rat: hemorrhages and dysplasias may lead to retinal detachment, Curr. Eye Res. 11 (10), 939-953 (1992).PubMedCrossRefGoogle Scholar
  41. 41.
    I. C. Michaelson, N. Herz, E. Lewkowitz, and D. Kertesz, Effect of increased oxygen on the development of the retinal vessels, Brit. J. Ophthal. 38 (10), 577-587 (1954).PubMedCrossRefGoogle Scholar
  42. 42.
    D. R. Senger, S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. S. Harvey, and H. F. Dvorak, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science 219 (4587), 983-985 (1983).PubMedCrossRefGoogle Scholar
  43. 43.
    P. J. Keck, S. D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder, and D. T. Connolly, Vascular permeability factor, and endothelial cell mitogen related to PDGF, Science 246 (4935), 1309-1312 (1989).PubMedCrossRefGoogle Scholar
  44. 44.
    D. W. Leung, G. Cachianes, W. J. Kuang, D. V. Goeddel, and N. Ferrara, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science 246 (4935), 1306-1309 (1989).PubMedCrossRefGoogle Scholar
  45. 45.
    N. Ferrara, K. Houck, L. Jakeman, and D. W. Leung, Molecular and biological properties of the vascular endothelial growth factor family of proteins, Endocr. Rev. 13 (1), 18-32 (1992).PubMedCrossRefGoogle Scholar
  46. 46.
    K. J. Kim, B. Li, J. Winer J, M. Armanini, N. Gillett, H. S. Phillips, and N. Ferrara, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature 362 (6423), 841-844 (1993).Google Scholar
  47. 47.
    N. Ferrara and T. Davis-Smyth, The biology of vascular endothelial growth factor, Endocr. Rev. 18 (1), 4-25 (1997).PubMedCrossRefGoogle Scholar
  48. 48.
    A. P. Adamis, J. W. Miller, M. T. Bernal, D. J. D’Amico, J. Folkman, T. K. Yeo, and K. T. Yeo, Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy, Am. J. Ophthalmol. 118 (4), 445-450 (1994).PubMedGoogle Scholar
  49. 49.
    L. P. Aiello, R. L. Avery, P. G. Arrigg, B. A. Keyt, H. D. Jampel, S. T. Shah, L. R. Pasquale, H. Thieme, M. A. Iwamoto, and J. E. Park, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N. Engl. J. Med. 331 (22), 1480-1487 (1994).CrossRefGoogle Scholar
  50. 50.
    G. Gao, Y. Li, D. Zhang, S. Gee, C. Crosson, and J. Ma, Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization, FEBS Lett. 489 (2-3), 270-276 (2001).PubMedCrossRefGoogle Scholar
  51. 51.
    E. A. Pierce, E. D. Foley, and L. E. Smith, Regulation of vascular endothelial cell growth factor by oxygen in a model of retinopathy of prematurity, Arch. Ophthalmol. 114 (10), 1219-1228 (1996).PubMedGoogle Scholar
  52. 52.
    D. Shweiki, A. Itin, D. Soffer, and E. Keshet, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature 359 (6398), 843-845 (1992).PubMedCrossRefGoogle Scholar
  53. 53.
    E. A. Pierce, R. L. Avery, E. D. Foley, L. P. Aiello, and L. E. Smith, Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization, Proc. Natl. Acad. Sci. USA 92 (3), 905-909 (1995).Google Scholar
  54. 54.
    D. A. Simpson, G. M. Murphy, T. Bhaduri , T. A. Gardiner, D. B. Archer, and A. W. Stitt, Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia, Biochem. Biophys. Res. Commun. 262 (2), 333-340 (1999).PubMedCrossRefGoogle Scholar
  55. 55.
    H. Ozaki, H. Hayashi, S. A. Vinores, Y. Moromizato, P. A. Campochiaro, and K. Oshima, Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates, Exp. Eye Res. 64 (4), 505-517 (1997).PubMedCrossRefGoogle Scholar
  56. 56.
    H. Ozaki, A. Y. Yu, N. Della, K. Ozaki, J. D. Luna, H. Yamada, S. F. Hackett, N. Okamoto, D. J. Zack, G. L. Semenza, and P. A. Campochiaro, Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression, Invest. Ophthalmol. Vis. Sci. 40 (1), 82-189 (1999).Google Scholar
  57. 57.
    L. P. Aiello, E. A. Pierce, E. D. Foley, H. Takagi, H. Chen, L. Riddle, N. Ferrara, G. L. King, and L. E. Smith, Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins, Proc. Natl. Acad. Sci. USA 92 (23), 10457-10461 (1995).Google Scholar
  58. 58.
    T. Tobe, N. Okamoto, M. A. Vinores, N. L. Derevjanik, S. A. Vinores, D. J. Zack, and P. A. Campochiaro, Evolution of neovascularization in mice with overexpresion of vascular endothelial growth factor in photoreceptors, Invest. Ophthalmol. Vis. Sci. 39 (1), 180-188 (1998).PubMedGoogle Scholar
  59. 59.
    W. T. Deng, Z. Yan, A. Dinculescu, J. Pang, J. T. Teusner, N. G. Cortez, K. I. Berns, and W. W. Hauswirth, Adeno-associated virus mediated expression of vascular endothelial growth factor peptides inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy, Hum. Gene Ther. 16, 1247-1254 (2005).PubMedCrossRefGoogle Scholar
  60. 60.
    A. P. Adamis, D. T. Shima, M. J. Tolentino, E. S. Gragoudas, N. Ferrara, J. Folkman, P. A. D’Amore, and J. W. Miller, Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovasculariztion in a nonhuman primate, Arch. Ophthalmol. 114 (1), 66-71 (1996).PubMedGoogle Scholar
  61. 61.
    F. Kinose, G. Roscilli, S. Lamartina, K. D. Anderson, F. Bonelli, S. G. Spence, G. Ciliberto, T. F. Vogt, D. J. Holder, C. Toniatti, and C. J. Thut, Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor, Mol. Vis. 11, 366-373 (2005).PubMedGoogle Scholar
  62. 62.
    R. Rota, T. Riccioni, M. Zaccarini, S. Lamartina, A. D. Gallo, A. Fusco, I. Kovesdi, E. Balestrazzi, D. C. Abeni, R. R. Ali, and M. C. Capogrossi, Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer, J. Gene Med. 6(9), 992-1002 (2004).PubMedCrossRefGoogle Scholar
  63. 63.
    E. W. Ng, D. T. Shima, P. Calias, E. T. Cunningham, D. R. Guyer, and A. P. Adamis, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov. 5 (2), 123-132 (2006).PubMedCrossRefGoogle Scholar
  64. 64.
    R. M. Rich, P. J. Rosenfeld, C. A. Puliafito, S. R. Dubovy, J. L. Davis, H. W. Flynn, S. Gonzalez, W. J. Feuer, R. C. Lin, G. A. Lalwani, J. K. Nguyen, and G. Kumar, Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration, Retina 26 (5), 495-511 (2006).PubMedCrossRefGoogle Scholar
  65. 65.
    A. D. Wright, E. M. Kohner, N. W. Oakley, M. Hartog, G. F. Joplin, and T. R. Fraser, Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation, Br. Med. J. 2 (653), 346-348 (1969).PubMedCrossRefGoogle Scholar
  66. 66.
    L. E. Smith, J. J. Kopchick, W. Chen, J. Knapp, F. Kinose, D. Daley, E. Foley, R. G. Smith, and J. M. Schaeffer, Essential role of growth hormone in ischemia-induced retinal neovascularization, Science 276 (5319), 1706-1709 (1997).PubMedCrossRefGoogle Scholar
  67. 67.
    L. E. Smith, W. Shen, C. Perruzzi, S. Soker, F. Kinose, X. Xu, G. Rovinson, S. Driver, J. Bischoff, B. Zhang, J. M. Schaeffer, and D. R. Senger, Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor, Nat. Med. 5 (12), 1390-1395 (1999).PubMedCrossRefGoogle Scholar
  68. 68.
    T. Kondo, D. Vicent, K. Suzuma, M. Yanagisawa, G. L. King, M. Holzenberger, and C. R. Kahn, Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization, J. Clin. Invest. 111 (12), 1835-1842 (2003).PubMedCrossRefGoogle Scholar
  69. 69.
    A. Das, A. McLamore, W. Song, and P. G. McGuire, Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor, Arch. Ophthalmol. 117 (4), 498-503 (1999).PubMedGoogle Scholar
  70. 70.
    J. Luna, T. Tobe, S. A. Mousa, T. M. Reilly, and P. A. Campochiaro, Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model, Lab. Invest. 75 (4), 563-573 (1996).PubMedGoogle Scholar
  71. 71.
    M. Friedlander, C. L. Theesfeld, M. Sugita, M. Fruttiger, M. A. Thomas, S. Chang, and D. A. Cheresh, Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases, Proc. Natl. Acad. Sci. USA 93 (18), 9764-9769 (1996).Google Scholar
  72. 72.
    H. Hammes, M. Brownlee, A. Jonczyk, A. Sutter, and K. T. Preissner, Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, Nat. Med. 2 (5), 529-533 (1996).PubMedCrossRefGoogle Scholar
  73. 73.
    S. Davis, T. H. Aldrich, and P. F. Jones, Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning, Cell 87 (7), 1161-1169 (1996).PubMedCrossRefGoogle Scholar
  74. 74.
    P. C. Maisonpierre, C. Suri, P. F. Jones, S. Bartunkova, S. J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T. H. Aldrich, N. Papadopoulos, T. J. Daly, S. Davis, T. N. Sato, G. D. Yancopoulos, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis, Science 277, 55-60 (1997).PubMedCrossRefGoogle Scholar
  75. 75.
    D. Hanahan, Signaling vascular morphogenesis and maintenance, Science 277(5322), 48-50 (1997).PubMedCrossRefGoogle Scholar
  76. 76.
    J. Folkman and P. A. D’Amore, Blood vessel formation: What is its molecular basis, Cell 87 (7), 1153-1155 (1996).PubMedCrossRefGoogle Scholar
  77. 77.
    N. W. Gale and G. D. Yancopoulos, Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development, Genes Dev. 13 (9), 1055-1066 (1999).PubMedGoogle Scholar
  78. 78.
    G. D. Yancoupolos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash, Vascular-specific growth factors and blood vessel formation, Nature 407 (6801), 242-248 (2000).CrossRefGoogle Scholar
  79. 79.
    H. Nambu, R. Nambu, Y. Oshima, S. F. Hackett, G. Okoye, S. Wiegand, G. Yancopoulos, D. J. Zack, and P. A. Campochiaro, Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier, Gene Therapy 11 (10), 865-873 (2004).PubMedCrossRefGoogle Scholar
  80. 80.
    H. Nambu, N. Umeda, S. Kachi, Y. Oshima, H. Akiyama, R. Nambu, and P. A. Campochiaro, Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization, J. Cell Phys. 204 (1), 227-235 (2005).CrossRefGoogle Scholar
  81. 81.
    S. Sarlos, B. Rizkalla, C. J. Moravski, Z. Cao, M. E. Cooper, and J. L. Wilkinson-Berka, Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin, Am. J. Pathol. 163 (3), 879-887 (2003).PubMedGoogle Scholar
  82. 82.
    S. F. Hackett, H. Ozaki, R. W. Strauss, K. Wahlin, C. Suri, P. Maisonpierre, G. Yancopoulos, and P. A. Campochiaro, Angiopoietin 2 expression in the retina: up-regulation during physiologic and pathologic neovascularization, J. Cell Physiol. 184(3), 275-284 (2000).PubMedCrossRefGoogle Scholar
  83. 83.
    S. F. Hackett, S. Wiegand, G. Yancopoulos, and P. A. Campochiaro, Angiopoietin-2 plays an important role in retinal angiogenesis, J. Cell Physiol. 192 (2), 182-187 (2002).Google Scholar
  84. 84.
    N. Umeda, H. Ozaki, H. Hayashi, and K. Oshima, Expression of ephrinB2 and its receptors on fibroproliferative membranes in ocular angiogenic diseases, Am. J. Ophthalmol. 138 (2), 270-279 (2004).PubMedCrossRefGoogle Scholar
  85. 85.
    J. J. Steinle, C. J. Meininger, U. Chowdhury, G. Wu, and H. J. Granger, Role of ephrin B2 in human retinal endothelial cell proliferation and migration, Cell Signal 15 (11), 1011-1017 (2003).Google Scholar
  86. 86.
    D. O. Zamora, M. H. Davies, S. R. Planck, J. T. Rosenbaum, and M. R. Powers, Soluble forms of ephrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy, Invest. Ophthalmol. Vis. Sci. 46 (6), 2175-2182 (2005).PubMedCrossRefGoogle Scholar
  87. 87.
    N. Cheng, D. M. Brantley, H. Liu, W. Fanslow, D. P. Cerretti, K. N. Bussell, A. Reith, D. Jackson, and J. Chen, Blockade of EphA receptor tyrosine kinase activation inhibits VEGF-induced angiogenesis, Mol. Cancer Res. 1 (1), 2-11 (2002).PubMedCrossRefGoogle Scholar
  88. 88.
    J. Chen, D. Hicks, D. Brantley-Sieders, N. Cheng, G. W. McCollum, X. Qi-Werdich, and J. Penn, Inhibition of retinal neovascularization by soluble EphA2 receptor, Exp. Eye Res. 82 (4), 664-673 (2006).PubMedCrossRefGoogle Scholar
  89. 89.
    W. Smalley and R. N. DuBois, Colorectal cancer and nonsteroidal anti-inflammatory drugs, Adv. Pharmacol. 39, 1-20 (1997).Google Scholar
  90. 90.
    N. B. Nandgaonkar, T. Rotschild, K. Yu, and R. D. Higgins, Indomethacin improves oxygen-induced retinopathy in the mouse, Pediatr. Res. 46 (2), 184-188 (1999).PubMedCrossRefGoogle Scholar
  91. 91.
    J. Sharma, S. M. Barr, Y. Geng, Y. Yun, and R. D. Higgins, Ibuprofen improves oxygen-induced retinopathy in a mouse model, Curr. Eye Res. 27 (5), 309-314 (2003).PubMedCrossRefGoogle Scholar
  92. 92.
    K. Takahashi, Y. Saishin, Y. Saishin, K. Mori, A. Ando, S. Yamamoto, Y. Oshima, H. Nambu, M. B. Melia, D. P. Bingaman, and P. A. Campochiaro, Topical nepafenac inhibits ocular neovascularization, Invest. Ophthalmol. Vis. Sci. 44 (1), 409-415 (2003).PubMedCrossRefGoogle Scholar
  93. 93.
    J. L. Wilkinson-Berka, N. S. Alousis, D. J. Kelly, and R. E. Gilbert, COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity, Invest. Ophthalmol. Vis. Sci. 44 (3), 974-979 (2003).PubMedCrossRefGoogle Scholar
  94. 94.
    C. J. Barnstable and J. Tombran-Tink, Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential, Prog. Retin. Eye Res. 23 (5), 561-577 (2004).PubMedCrossRefGoogle Scholar
  95. 95.
    D. W. Dawson, O. V. Volpert, P. Gillis, S. E. Crawford, H. Xu, W. Benedict, and N. P. Bouck, Pigment epithelium-derived factor: a potent inhibitor of angiogenesis, Science 285 (5425), 245-248 (1999).Google Scholar
  96. 96.
    R. Z. Renno, A. I. Youssri, N. Michaud, E. S. Gragoudas, and J. W. Miller, Expression of pigment epithelium-derived factor in experimental choroidal neovascularization, Invest. Ophthalmol. Vis. Sci. 43 (5), 1574-1580 (2002).PubMedGoogle Scholar
  97. 97.
    E. J. Duh, H. S. Yang, I. Suzuma I, M. Miyagi, E. Youngman, K. Mori, M. Katai, L. Yan, K. Suzuma, K. West, S. Davarya, P. Tong, P. Gehlbach, J. Pearlman, J. W. Crabb, L. P. Aiello, P. A. Campochiaro, and D. J. Zack, Pigment epithelium-derived factor suppresses ischemia-induced retinal neovasculariztion and VEGF-induced migration and growth, Invest. Ophthalmol. Vis. Sci. 43 (3), 821-829 (2002).PubMedGoogle Scholar
  98. 98.
    A. Auricchio, K. C. Behling, A. M. Maguire, E. M. O’Connor, J. Bennett, J. M. Wilson, and M. J. Tolentino, Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents, Mol. Ther. 6 (4), 490-494 (2002).PubMedCrossRefGoogle Scholar
  99. 99.
    V. Stellmach, S. E. Crawford, W. Zhou, and N. Bouck, Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor, Proc. Natl. Acad. Sci. USA 98 (5), 2593-2597 (2001).Google Scholar
  100. 100.
    K. Mori, P. Gehlbach, A. Ando, D. McVey, L. Wei, and P. A. Campochiaro, Regression of ocular neovasculariztion in response to increased expression of pigment epithelium-derived factor, Invest. Ophthalmol. Vis. Sci. 43 (7), 2428-2434, (2002).PubMedGoogle Scholar
  101. 101.
    A. W. Stitt, D. Graham, and T. A. Gardiner, Ocular wounding prevents pre-retinal neovascularization and upregulated PEDF expression in the inner retina, Mol. Vis. 10, 432-438 (2004).PubMedGoogle Scholar
  102. 102.
    J. S. Penn, G. W. McCollum, J. M. Barnett JM, X. Q. Werdich, K. A. Koepke, and V. S. Rajaratnam, Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor , Invest. Ophthalmol. Vis. Sci. 47 (1), 405-414 (2006).Google Scholar
  103. 103.
    P.A. Campochiaro, Q. D. Nguyen, S. M. Shah, M. L. Klein, E. Holz, R. N. Frank, D. A. Saperstein, A. Gupta, J. T. Stout, J. Macko, R. DiBartolomeo, and L. L. Wei, Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial , Hum. Gene Ther. 17 (2), 167-176 (2006).PubMedCrossRefGoogle Scholar
  104. 104.
    C. A. May, A. V. Ohlmann, H. Hammes, and U. H. Spandau, Proteins with an endostatin-like domain in a mouse model of oxygen-induced retinopathy, Exp. Eye Res. 82 (2), 341-348 (2006).PubMedCrossRefGoogle Scholar
  105. 105.
    T. A. Drixler, I. H. Borel Rinkes, E. D. Ritchie, F. W. Treffers, T. J. van Vroonhoven, M. F. Gebbink, and E. E. Voest, Angiostatin inhibits pathological but not physiological retinal angiogenesis, Invest. Ophthalmol. Vis. Sci. 42 (13), 3325-3330 (2001).PubMedGoogle Scholar
  106. 106.
    T. Igarashi, K. Miyake, K. Kato, A Watanabe, M. Ishizaki, K. Ohara, and T. Shimada, Lenitivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model, Gene Ther. 10 (3), 219-226 (2003).PubMedCrossRefGoogle Scholar
  107. 107.
    A. Shafiee, J. S. Penn, H. C. Krutzsch, J. K. Inman, D. D. Roberts, D. A. Blake, Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1, Invest. Ophthalmol. Vis. Sci. 41 (8), 2378-2388 (2000).PubMedGoogle Scholar
  108. 108.
    J. Schlessinger, I. Lax, and M. Lemmon, Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? Cell 83 (3), 357–360 (1995).PubMedCrossRefGoogle Scholar
  109. 109.
    F. Blasi, J. D. Vassalli, and K. Dano, Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , J. Cell. Biol. 104 (4), 801-804 (1987).PubMedCrossRefGoogle Scholar
  110. 110.
    O. Saksela, Plasminogen activation and regulation of pericellular proteolysis, Biochim. Biophys. Acta. 823 (1), 35-65 (1985).PubMedGoogle Scholar
  111. 111.
    J. S. Penn and V. S. Rajaratnam, Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity, Invest. Ophthalmol. Vis. Sci. 44 (12), 5423-5429 (2003).PubMedCrossRefGoogle Scholar
  112. 112.
    L. E. Bullard, X. Qi, and J.S. Penn, Role for extracellular signal-responsive kinase-1 and -2 in retinal angiogenesis, Invest. Ophthalmol. Vis. Sci. 44 (4), 1722-1731 (2003).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Susan E. Yanni
    • 1
  • Gary W. McCollum
    • 2
  • John S. Penn
    • 1
    • 2
  1. 1.Departments of Cell & Developmental BiologyVanderbilt University School of MedicineNashville
  2. 2.Ophthalmology and Visual SciencesVanderbilt University School of MedicineNashville

Personalised recommendations